BioCardia, Inc. (BCDA), a clinical-stage regenerative medicine company, and CART-Tech, B.V., a provider of vendor independent platform technology for augmented fluoroscopy during cardiac interventions, Wednesday said they have entered into an agreement to develop and sell Heart3D Fusion Imaging.
Under the partnership, the companies plan to advance Heart3D Fusion Imaging for biotherapeutic interventions and cardiac biopsy.
The system is expected to be sold initially as a research tool with support services for partners in preclinical studies and then approved for standard clinical practice.
BioCardia will have distribution rights for biotherapeutic delivery across the world, and for cardiac biopsy in the United States. All other distribution rights remain with CART-Tech.
As part of the partnership, BioCardia has licensed global rights to CART-Tech intellectual property for the fields of biotherapeutic intervention. CART-Tech has licensed global rights to BioCardia intellectual property for cardiac resynchronization therapy.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.